Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FKBP1A | P62942 | 3/20 | 0.39 |
| ▸ | GSK3B | P49841 | 7/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.39 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | FSHR | P23945 | 2/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | CTSL | P07711 | 1/20 | 0.35 |
| ▸ | CTSB | P07858 | 1/20 | 0.35 |
| ▸ | CTSS | P25774 | 1/20 | 0.35 |
| ▸ | CYP46A1 | Q9Y6A2 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1975690 | 0.79 | CYP2D6 (0.42) | FKBP1AGSK3BCYP2D6CYP3A4CYP2C9 | |
| SCHEMBL1831688 | 0.78 | CYP2D6 (0.42) | GSK3BCYP2D6CYP3A4CYP2C9GRIN2B | |
| SCHEMBL15512999 | 0.77 | GSK3B (0.44) | GSK3BCYP2D6 | |
| SCHEMBL1832408 | 0.77 | GSK3B (0.42) | GSK3BCYP2D6CYP46A1 | |
| SCHEMBL3273975 | 0.73 | GSK3B (0.47) | GSK3BCYP2D6POLB | |
| SCHEMBL2066100 | 0.70 | GSK3B (0.43) | GSK3BCYP2D6CYP3A4 | |
| SCHEMBL3278253 | 0.70 | ATM (0.45) | GSK3BCYP2D6POLB | |
| SCHEMBL3280949 | 0.70 | GSK3B (0.45) | GSK3BCYP2D6POLB | |
| SCHEMBL4385699 | 0.68 | GSK3B (0.35) | GSK3BCYP2D6CYP3A4 | |
| SCHEMBL4387999 | 0.68 | GSK3B (0.37) | GSK3BTSHRCYP3A4POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110144132-A1 | SUBSTITUTED PYRIMIDIN-4-ONE DERIVATIVES | SANOFI-AVENTIS (FR) | 2011-06-16 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110144132-A1 | SUBSTITUTED PYRIMIDIN-4-ONE DERIVATIVES | TYMP, DHFR, DPYD | FKBP1A 3961/4885GSK3B 3574/4885CYP2D6 221/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.